UTX Subsidiary to Be Embraer E-Jet Maintenance Provider and 2 Other Dow Movers to Watch

United Technologies Corp. (NYSE:UTX): Current price $93.81

The UTX subsidiary UTC Aerospace Systems, has been chosen by Air France to be the maintenance, repair and overhaul services provider for an array of actuation, air management and electrical systems on Embraer E-Jet fleets which Air France supports for its customers. This selection marks UTC Aerospace Systems’ first contract for E-Jet repairs with the French carrier. The three-year arrangement covers services for the electric power equipment, electric power generating system, air management system, and flight systems on the airline’s ERJ-170, ERJ-175, and ERJ-190 aircraft. The labor will be performed by subsidiaries of UTC Aerospace Systems in Dijon and Maastricht.

UTX

Verizon Communications (NYSE:VZ) Current Price: 50.60

Verizon recently finished LTE deployment in 500 markets, creating the largest 4G LTE network in the United States; the network covers almost 99 percent of its 3G network areas, and caters to in excess of 298 million of the population. During increasing demand of LTE services, the company believes that expansion plans in this space not only support growth in the future, but will also solidify its position as one of the top wireless providers. To make LTE deployment easier, Verizon remains concentrated upon fulfilling spectrum requirements.

VZ

Merck & Co. (NYSE:MRK): Current price $46.54

On Tuesday, Merck announced that the FDA has cleared new labeling for Isentress (raltegravir) Film-coated Tablets, the company’s integrase inhibitor for the treatment of  HIV-1 infection in adult patients as part of combination HIV therapy. The updated information now includes 240-week results from the STARTMRK study, which was the longest double-blind Phase III non-inferiority study evaluating an integrase inhibitor in treatment-naïve adult patients suffering with HIV-1 infection. The results indicated that the regimen containing Isentress in combination therapy showed long-term viral suppression and a greater immunologic response than did the efavirenz-containing regimen, along with a proven, long-term safety and tolerability profile through 240 weeks in previously untreated  (treatment-naïve) adult HIV-1 infected patients.

MRK

Investing Insights: Will Siemens See Higher Prices?